In recent years, metabolomics is emerging as a powerful platform for discovering pathways linked to diseases, including T2DM, cardiovascular disease, hepatic injury, neurodegenerative and various tumors, etc. Current studies also show that the occurrence and development of some diseases, especially metabolic diseases and tumors, are closely related to the balance of small molecular metabolites in the body. The relatively stable nature of the human metabolomics makes metabolic pathways a novel therapeutic/diagnosis target to exert their therapeutic/adverse effects. For example, the evidence suggests that chronic social stress diminished cAMP synthesis in neurons so that damaging blood-brain barrier integrity in the nucleus accumbens. Also, it will promote stress vulnerability, gut microbe formed phenylacetylglutamine (PAGln) contributes to cardiac disease. While target discovery relies on molecular biology, metabolomics is relatively a novel approach.
Advances in metabolomics technology have helped the discovery of targets for diagnosis and treatment of complex diseases. Metabolomics platform aimed to measure concentrations of endogenous metabolites to help map complex diseases and characterize drug response. Some exciting work has discovered novel biomarkers that can identify individuals who may have a high response to some treatment or diagnose some diseases more accurately. Other studies have helped to find key metabolic pathways related to drug mechanisms or toxicity. Metabolomics technology plays an important role in precision medicine.
This Research Topic welcomes leading experts to submit their original studies on animal models or human subjects. Review articles that help understand the role of metabolic pathways of small molecule endogenous substances in the treatment or diagnosis of metabolic disease and various tumors, reveal the mechanisms underlying the pharmacological interactions between metabolic target and available intervention strategies that provide further insights in the treatment of metabolic disorders and tumors.
The research topic includes, but is not limited to:
• Metabolomic applications within man, including pre-clinical and clinical
• Metabolite target analysis of which reveals new pharmacological targets for the treatment of metabolic disorders and tumors
• Interventions to improve metabolic disorders and tumors base on metabolic profiling
• New technologies and methods for target discovery
• Drug development and treatment based on target discovery
In recent years, metabolomics is emerging as a powerful platform for discovering pathways linked to diseases, including T2DM, cardiovascular disease, hepatic injury, neurodegenerative and various tumors, etc. Current studies also show that the occurrence and development of some diseases, especially metabolic diseases and tumors, are closely related to the balance of small molecular metabolites in the body. The relatively stable nature of the human metabolomics makes metabolic pathways a novel therapeutic/diagnosis target to exert their therapeutic/adverse effects. For example, the evidence suggests that chronic social stress diminished cAMP synthesis in neurons so that damaging blood-brain barrier integrity in the nucleus accumbens. Also, it will promote stress vulnerability, gut microbe formed phenylacetylglutamine (PAGln) contributes to cardiac disease. While target discovery relies on molecular biology, metabolomics is relatively a novel approach.
Advances in metabolomics technology have helped the discovery of targets for diagnosis and treatment of complex diseases. Metabolomics platform aimed to measure concentrations of endogenous metabolites to help map complex diseases and characterize drug response. Some exciting work has discovered novel biomarkers that can identify individuals who may have a high response to some treatment or diagnose some diseases more accurately. Other studies have helped to find key metabolic pathways related to drug mechanisms or toxicity. Metabolomics technology plays an important role in precision medicine.
This Research Topic welcomes leading experts to submit their original studies on animal models or human subjects. Review articles that help understand the role of metabolic pathways of small molecule endogenous substances in the treatment or diagnosis of metabolic disease and various tumors, reveal the mechanisms underlying the pharmacological interactions between metabolic target and available intervention strategies that provide further insights in the treatment of metabolic disorders and tumors.
The research topic includes, but is not limited to:
• Metabolomic applications within man, including pre-clinical and clinical
• Metabolite target analysis of which reveals new pharmacological targets for the treatment of metabolic disorders and tumors
• Interventions to improve metabolic disorders and tumors base on metabolic profiling
• New technologies and methods for target discovery
• Drug development and treatment based on target discovery
